Drug
Umibecestat clinical trials
Also written CNP520.
- studies test it
- 3
- open now
- 0
- in phase 3
- 2
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Umibecestat is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseTerminatedPhase 2/3Novartis PharmaceuticalsNCT03131453Written as CNP520 50mg
- A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseTerminatedPhase 2/3Novartis PharmaceuticalsNCT02565511Written as CNP520
- Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of AgeCompletedPhase 2Novartis PharmaceuticalsNCT02576639Written as CNP520
Codes
What other systems call Umibecestat · ClinicalTrials.gg INT000993
- MeSH (NLM) C000628578UmibecestatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4612B80545UMIBECESTATConfirmed FDA, NLM
- NCI Thesaurus C166726UmibecestatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628578 | Umibecestat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4612B80545 | UMIBECESTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C166726 | Umibecestat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.